Norge - norsk - Statens legemiddelverk

takeda as - cyanokobalamin - injeksjonsvæske, oppløsning - 1 mg/ ml

Norge - norsk - Statens legemiddelverk

takeda as - adrenalintartrat - injeksjonsvæske, oppløsning - 0.1 mg/ ml

Norge - norsk - Statens legemiddelverk

takeda as - adrenalintartrat - injeksjonsvæske, oppløsning - 1 mg/ ml

Norge - norsk - Statens legemiddelverk

takeda as - dopaminhydroklorid - konsentrat til infusjonsvæske - 10 mg/ ml

Norge - norsk - Statens legemiddelverk

takeda as - hydroksokobalaminklorid - injeksjonsvæske, oppløsning - 1 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - selektive immunosuppressiva - ulcerøs colitisentyvio er indisert for behandling av voksne pasienter med moderat til alvorlig aktiv ulcerøs kolitt som har hatt utilstrekkelig respons med, mistet svar på, eller var intolerant å enten konvensjonell terapi eller en tumor nekrose faktor alfa (tnfa) antagonist. crohns diseaseentyvio er indisert for behandling av voksne pasienter med moderat til alvorlig aktiv crohns sykdom som har hatt utilstrekkelig respons med, mistet svar på, eller var intolerant å enten konvensjonell terapi eller en tumor nekrose faktor alfa (tnfa) antagonist. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda france sas - mifamurtide - osteosarkom - immunostimulants, - mepact er indisert hos barn, ungdom og unge for behandling av høyverdig resektabel ikke-metastatisk osteosarkom etter makroskopisk fullstendig kirurgisk reseksjon. det brukes i kombinasjon med postoperativ multi-agent kjemoterapi. sikkerhet og effekt har blitt vurdert i studier av pasienter fra 2 til 30 år ved første diagnose.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Den europeiske union - norsk - EMA (European Medicines Agency)

corza medical gmbh - human fibrinogen, human trombin - hemostase, kirurgisk - antihemoragika - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.